Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
caplacizumab + corticosteroids + anti-cd20 antibody
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
A combination regimen of **caplacizumab**, **corticosteroids**, and an **anti-CD20 antibody** (most commonly rituximab) is used for the management of **acquired thrombotic thrombocytopenic purpura (aTTP)**. Caplacizumab is a humanized bivalent Nanobody that targets the A1-domain of von Willebrand factor, thereby blocking platelet aggregation and preventing microvascular thrombosis. Corticosteroids act as immunosuppressive agents to dampen the autoimmune response. Anti-CD20 antibodies (such as rituximab or obinutuzumab) deplete B cells, reducing the formation of pathogenic autoantibodies against ADAMTS13. This combination approach addresses both immediate microthrombosis and underlying autoimmunity, leading to improved platelet recovery, lower relapse rates, and improved survival in aTTP patients[1][3][7][8][9].
- Other names
- caplacizumab + corticosteroids + anti-cd20 antibody
02
Targets
Beyond the preview
Go deeper on caplacizumab + corticosteroids + anti-cd20 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on caplacizumab + corticosteroids + anti-cd20 antibody.